Investigadors IDIBELL de la Unitat funcional de Neuro-oncologia de l\u2019Hospital Universitari de Bellvitge \u2013 Institut Catal\u00e0 d\u2019Oncologia, liderats pel Dr. Jordi Bruna, han testejat amb \u00e8xit una nova mol\u00e8cula capa\u00e7 d\u2019evitar el desenvolupament de neuropaties perif\u00e8riques derivades de l\u2019administraci\u00f3 de quimioter\u00e0pia en pacients de c\u00e0ncer, especialment en c\u00e0ncer de colon, la tercera neoplasia m\u00e9s freq\u00fcent del m\u00f3n. La mol\u00e8cula, que presenta un mecanisme d\u2019acci\u00f3 totalment nou, suposaria el primer tractament d’efic\u00e0cia establerta per combatre aquesta complicaci\u00f3, per a la que fins ara no existeix cap tractament efectiu aprovat. <\/p>\n
Un dels principals efectes adversos de certs quimioter\u00e0pics utilitzats en el tractament de c\u00e0ncers \u00e9s la neuropatia perif\u00e8rica, que pot provocar sensaci\u00f3 de formigueig, adormiment, dolor o alteracions de la funcionalitat dels pacients, entre d\u2019altres. Aquesta complicaci\u00f3, fins ara, s’ha assumit com cert peatge a pagar malgrat tenir un impacte negatiu demostrat en la qualitat de vida del pacient, encarir les seves cures i moltes vegades impedir l’administraci\u00f3 complerta i efectiva del tractament citost\u00e0tic, amb la potencial disminuci\u00f3 de les probabilitats de superviv\u00e8ncia del pacient que aix\u00f2 comporta. <\/p>\n
Els investigadors de la Unitat del HUB-ICO-IDIBELL van identificar una nova mol\u00e8cula – desenvolupada pel laboratori catal\u00e0 Esteve \u2013 com a candidata per<\/p>\n
evitar l\u2019aparici\u00f3 d\u2019aquest efecte advers. \u201cGr\u00e0cies a un acord de col\u00b7laboraci\u00f3 p\u00fablic-privada, hem pogut dissenyar un estudi cl\u00ednic de fase 2b (randomitzat amb placebo), fet que ha perm\u00e8s obtenir molt\u00edssima informaci\u00f3 a nivell cient\u00edfic \u2013 actuaci\u00f3 sobre el dolor,<\/p>\n
fisiopatologia –<\/p>\n
i extreure conclusions pel que fa al potencial del f\u00e0rmac en la prevenci\u00f3 de neuropaties durant el tractament citost\u00e0tic\u201d, explica el Dr. Bruna, l\u00edder de l\u2019estudi. <\/p>\n
Els resultats del treball demostren una disminuci\u00f3 en l\u2019aparici\u00f3 de trastorns associats a la disfunci\u00f3 dels nervis en aquells pacients de c\u00e0ncer que van prendre el nou f\u00e0rmac. \u201cQuan es va dissenyar l\u2019assaig, les dades de seguretat provinents del assajos previs limitaven la durada del tractament amb la nova mol\u00e8cula i aix\u00f2 va fer que hagu\u00e9ssim de treballar a dosis baixes en relaci\u00f3 a la durada del tractament quimioter\u00e0pic, per\u00f2 malgrat tot hem obtingut resultats positius i ara ens trobem amb prou informaci\u00f3 com per poder ampliar la durada del tractament, amb la qual cosa esperem obtenir resultats encara m\u00e9s satisfactoris\u201d comenta l\u2019investigador de l\u2019IDIBELL. <\/p>\n
\u201cTenint en compte el ritme habitual dels assajos cl\u00ednics, i que les ag\u00e8ncies de medicaments solen cursar aprovacions r\u00e0pides en patologies greus i orfes de tractament, \u00e9s probable que el temps d\u2019arribada d\u2019aquest nou f\u00e0rmac al mercat sigui for\u00e7a breu, i ens trobar\u00edem davant del primer tractament disponible per a evitar aquest tipus de neuropaties. A m\u00e9s, \u00e9s un f\u00e0rmac amb d\u2019altres usos m\u00e8dics com a analg\u00e8sic no opioide\u201d, afegeix Bruna. En qualsevol cas, la millora del control del dolor i la reducci\u00f3 en l\u2019aparici\u00f3 de neuropaties greus representa sens dubte el benefici m\u00e9s destacat del desenvolupament d\u2019aquest noved\u00f3s f\u00e0rmac. <\/p>\n
Bruna J, Videla S, Argyriou AA, Velasco R, Villoria J, Santos C, Nadal C, Cavaletti G, Alberti P, Briani C, Kalofonos HP, Cortinovis D, Sust M, Vaqu\u00e9 A, Klein T, Plata-Salam\u00e1n C. Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial. Neurotherapeutics. 2017 Sep 18. doi: 10.1007\/s13311-017-0572-5. [Epub ahead of print]<\/p>\n","protected":false},"excerpt":{"rendered":"
La neuropatia perif\u00e8rica \u00e9s una complicaci\u00f3 molt freq\u00fcent del tractament amb quimioter\u00e0pia i pot acabar conduint a la suspensi\u00f3 preco\u00e7 del tractament. La col\u00b7laboraci\u00f3 entre recerca i ind\u00fastria permet identificar i testejar una nova mol\u00e8cula\u00a0 capa\u00e7 de combatre aquesta complicaci\u00f3. La mol\u00e8cula podria esdevenir el primer tractament existent per prevenir aquest efecte advers tant freq\u00fcent i millorar la qualitat de vida dels pacients de c\u00e0ncer. Refer\u00e8ncia de l\u2019article<\/p>\n","protected":false},"author":6,"featured_media":10637,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[1],"tags":[],"class_list":["post-7746","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sin-categorizar"],"publishpress_future_action":{"enabled":false,"date":"2024-12-30 06:38:08","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/7746","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=7746"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/7746\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/10637"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=7746"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=7746"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=7746"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}